{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:01:14Z","timestamp":1788483674766,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160711"],"award-info":[{"award-number":["82160711"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960680"],"award-info":[{"award-number":["81960680"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["53282160711"],"award-info":[{"award-number":["53282160711"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cbi.2022.110331","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T19:31:00Z","timestamp":1672083060000},"page":"110331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["7, 8-Dihydroxy-4-methyl coumarin alleviates cholestasis via activation of the Farnesoid X receptor in vitro and in vivo"],"prefix":"10.1016","volume":"370","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4017-9052","authenticated-orcid":false,"given":"Moath","family":"Refat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Ahmed A.Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin'an","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2022.110331_bib1","series-title":"Mechanisms of Proinflammatory Signaling during Cholestasis","author":"Allen","year":"2011"},{"issue":"8","key":"10.1016\/j.cbi.2022.110331_bib2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.cbi.2022.110331_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1751-2980.2010.00427.x","article-title":"Pharmacotherapy of cholestatic liver diseases","volume":"11","author":"Paumgartner","year":"2010","journal-title":"J. Digest. Dis."},{"issue":"3","key":"10.1016\/j.cbi.2022.110331_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/MOG.0b013e32832914b4","article-title":"Cholestasis and cholestatic syndromes","volume":"25","author":"Hirschfield","year":"2009","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.cbi.2022.110331_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jhep.2006.12.001","article-title":"New perspectives for the treatment of cholestasis: lessons from basic science applied clinically","volume":"46","author":"Boyer","year":"2007","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.cbi.2022.110331_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1590-8658(02)80033-0","article-title":"Bile acid-mediated hepatocyte apoptosis and cholestatic liver disease","volume":"34","author":"Guicciardi","year":"2002","journal-title":"Dig. Liver Dis."},{"issue":"5418","key":"10.1016\/j.cbi.2022.110331_bib7","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.cbi.2022.110331_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cbi.2022.110331_bib9","series-title":"Targeting FXR in Cholestasis,\u201d Bile Acids and Their Receptors","first-page":"299","author":"Keitel","year":"2019"},{"issue":"6","key":"10.1016\/j.cbi.2022.110331_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cbi.2022.110331_bib11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0168-8278(03)00397-0","article-title":"ABC transporter regulation by bile acids: where PXR meets FXR","volume":"39","author":"Kullak-Ublick","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cbi.2022.110331_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0065-2571(99)00022-9","article-title":"Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family","volume":"40","author":"Keppler","year":"2000","journal-title":"Adv. Enzym. Regul."},{"issue":"1","key":"10.1016\/j.cbi.2022.110331_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.gastro.2003.06.005","article-title":"Enterohepatic bile salt transporters in normal physiology and liver disease","volume":"126","author":"Kullak-Ublick","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cbi.2022.110331_bib14","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.cbi.2022.110331_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1751-2980.12378","article-title":"Role of farnesoid X receptor in cholestasis","volume":"17","author":"Yuan","year":"2016","journal-title":"J. Digest. Dis."},{"issue":"4","key":"10.1016\/j.cbi.2022.110331_bib16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/j.gastro.2015.02.037","article-title":"Targeting the FXR nuclear receptor to treat liver disease","volume":"148","author":"Neuschwander-Tetri","year":"2015","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cbi.2022.110331_bib17","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.cbi.2022.110331_bib18","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.28712","article-title":"Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice","volume":"64","author":"Xu","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cbi.2022.110331_bib19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs","volume":"47","author":"Urquhart","year":"2007","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.cbi.2022.110331_bib20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cbi.2022.110331_bib21","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"V Kowdley","year":"2018","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cbi.2022.110331_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.cbi.2022.110331_bib23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1080\/14656566.2016.1218471","article-title":"Obeticholic acid for the treatment of primary biliary cholangitis","volume":"17","author":"Ali","year":"2016","journal-title":"Expet Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.cbi.2022.110331_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12640-014-9507-7","article-title":"7, 8-Dihydroxy-4-methylcoumarin provides neuroprotection by increasing hippocalcin expression","volume":"27","author":"Jin","year":"2015","journal-title":"Neurotox. Res."},{"issue":"4","key":"10.1016\/j.cbi.2022.110331_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejmech.2004.09.002","article-title":"Synthesis of novel amino and acetyl amino-4-methylcoumarins and evaluation of their antioxidant activity","volume":"40","author":"Tyagi","year":"2005","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.cbi.2022.110331_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"16","key":"10.1016\/j.cbi.2022.110331_bib27","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"14","key":"10.1016\/j.cbi.2022.110331_bib28","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/bioinformatics\/btl150","article-title":"Molecular complexes at a glance: automated generation of two-dimensional complex diagrams","volume":"22","author":"Stierand","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cbi.2022.110331_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173498","article-title":"Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo","volume":"885","author":"Zhang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.cbi.2022.110331_bib30","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/ptr.6406","article-title":"Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled, double-blind clinical trial","volume":"33","author":"Cheraghpour","year":"2019","journal-title":"Phytother Res."},{"issue":"4","key":"10.1016\/j.cbi.2022.110331_bib31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/nu11040783","article-title":"Protective effect of hesperidin on the oxidative stress induced by an exhausting exercise in intensively trained rats","volume":"11","author":"Estruel-Amades","year":"2019","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.cbi.2022.110331_bib32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jbt.21799","article-title":"Hesperidin alleviates oxidative stress and upregulates the multidrug resistance protein 2 in isoniazid and rifampicin-induced liver injury in rats","volume":"30","author":"Zhang","year":"2016","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.cbi.2022.110331_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.taap.2018.04.015","article-title":"Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro","volume":"348","author":"Gao","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.cbi.2022.110331_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bjornsson","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cbi.2022.110331_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40264-018-0743-2","article-title":"Drug-induced liver injury: highlights of the recent literature","volume":"42","author":"Real","year":"2019","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.cbi.2022.110331_bib36","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cbi.2022.110331_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1476-5381.2008.00030.x","article-title":"Nuclear receptors as therapeutic targets in cholestatic liver diseases","volume":"156","author":"Zollner","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.cbi.2022.110331_bib38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.molmed.2003.10.002","article-title":"Molecular aspects of bile formation and cholestasis","volume":"9","author":"Arrese","year":"2003","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.cbi.2022.110331_bib39","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cbi.2022.110331_bib40","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.cbi.2022.110331_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.taap.2016.06.019","article-title":"Dioscin protects against ANIT--induced cholestasis via regulating Oatps, Mrp2 and Bsep expression in rats","volume":"305","author":"Jia","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110331_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2016.09.020","article-title":"Alpha-naphthylisothiocyanate impairs bile acid homeostasis through AMPK-FXR pathways in rat primary hepatocytes","volume":"370","author":"Li","year":"2016","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2022.110331_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jep.2017.07.031","article-title":"Analyzing the hepatoprotective effect of the Swertia cincta Burkillextract against ANIT-induced cholestasis in rats by modulating the expression of transporters and metabolic enzymes","volume":"209","author":"Xu","year":"2017","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.cbi.2022.110331_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.153153","article-title":"Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor","volume":"68","author":"Li","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cbi.2022.110331_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejphar.2016.07.032","article-title":"Effects of andrographolide on intrahepatic cholestasis induced by alpha-naphthylisothiocyanate in rats","volume":"789","author":"Khamphaya","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110331_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115248","article-title":"Picroside II alleviates liver injury induced by alpha-naphthylisothiocyanate through AMPK-FXR pathway","volume":"408","author":"Li","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.cbi.2022.110331_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2022.110331_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tiv.2018.08.001","article-title":"The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity","volume":"53","author":"Kamalian","year":"2018","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.cbi.2022.110331_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114666","article-title":"Untargeted liquid chromatography-mass spectrometry metabolomics to assess drug-induced cholestatic features in HepaRG\u00aecells","volume":"379","author":"Cuykx","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.cbi.2022.110331_bib50","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.xphs.2016.01.013","article-title":"Establishment of a drug-induced, bile acid-dependent hepatotoxicity model using HepaRG cells","volume":"105","author":"Susukida","year":"2016","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.cbi.2022.110331_bib51","doi-asserted-by":"crossref","first-page":"1640187","DOI":"10.1155\/2017\/1640187","article-title":"Upregulation of PDZK1 by Calculus Bovis Sativus May Play an Important Role in Restoring Biliary Transport Function in Intrahepatic Cholestasis","author":"Xiang","year":"2017","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"2","key":"10.1016\/j.cbi.2022.110331_bib52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/aps.2017.98","article-title":"D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress","volume":"39","author":"Zhao","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.cbi.2022.110331_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.apsb.2015.01.005","article-title":"Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration","volume":"5","author":"Li","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.cbi.2022.110331_bib54","first-page":"2012","article-title":"Bile acid signaling in liver metabolism and diseases","author":"Li","year":"2012","journal-title":"J. Lipids"},{"issue":"1","key":"10.1016\/j.cbi.2022.110331_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00253-016-8006-6","article-title":"Interaction of gut microbiota with bile acid metabolism and its influence on disease states","volume":"101","author":"Staley","year":"2017","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"10","key":"10.1016\/j.cbi.2022.110331_bib56","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis: thematic review series: bile acids","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722005403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722005403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:23:58Z","timestamp":1777386238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279722005403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":56,"alternative-id":["S0009279722005403"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2022.110331","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"7, 8-Dihydroxy-4-methyl coumarin alleviates cholestasis via activation of the Farnesoid X receptor in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2022.110331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110331"}}